Avrobio (AVRO) Releases Earnings Results, Misses Expectations By $2.51 EPS

Avrobio (NASDAQ:AVRO) announced its quarterly earnings data on Thursday. The company reported ($2.98) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($2.51), Bloomberg Earnings reports.

Shares of AVRO traded up $2.91 during midday trading on Friday, reaching $40.97. The stock had a trading volume of 21,200 shares, compared to its average volume of 128,091. Avrobio has a 1-year low of $26.51 and a 1-year high of $44.01.

A number of equities research analysts have recently weighed in on the stock. Wedbush assumed coverage on shares of Avrobio in a report on Monday, July 16th. They issued an “outperform” rating and a $38.00 price objective on the stock. Cowen assumed coverage on shares of Avrobio in a report on Monday, July 16th. They issued an “outperform” rating on the stock. Morgan Stanley assumed coverage on shares of Avrobio in a report on Monday, July 16th. They issued an “overweight” rating and a $37.00 price objective on the stock. Finally, Wells Fargo & Co assumed coverage on shares of Avrobio in a report on Monday, July 16th. They issued an “outperform” rating and a $40.00 price objective on the stock.

Avrobio Company Profile

AVROBIO, Inc, a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease.

Featured Article: Earnings Per Share

Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply